Spatiotemporal evolution of ventricular fibrillation
... recording array, each rotor occupied on average 12 6 4 cm2 . According to rough measurements of heart surface area, we estimate that the total number of rotors during fibrillation would be approximately 1–2 for rabbits, 5 for sheep, and 15 for humans (assuming the rotor density is the same in humans ...
... recording array, each rotor occupied on average 12 6 4 cm2 . According to rough measurements of heart surface area, we estimate that the total number of rotors during fibrillation would be approximately 1–2 for rabbits, 5 for sheep, and 15 for humans (assuming the rotor density is the same in humans ...
Spatial QRS-T angle predicts cardiac death in a
... angle in predicting cardiovascular mortality in a large, general hospital-based population. Our findings support the value of repolarization measures13–15 as determined by the spatial QRS-T angle as a tool for risk stratification. Although considered a marker of pathology from the early days of ECG, ...
... angle in predicting cardiovascular mortality in a large, general hospital-based population. Our findings support the value of repolarization measures13–15 as determined by the spatial QRS-T angle as a tool for risk stratification. Although considered a marker of pathology from the early days of ECG, ...
Advances in Valvular Heart Disease - DSpace Home
... people worldwide and is associated with considerable morbidity and mortality. The prevalence is increasing as the population ages, afflicting 2 to 3 percent of North Americans older than age 65.1 Until recently, the main treatment for AS was surgical aortic valve replacement (SAVR, AVR). Although hi ...
... people worldwide and is associated with considerable morbidity and mortality. The prevalence is increasing as the population ages, afflicting 2 to 3 percent of North Americans older than age 65.1 Until recently, the main treatment for AS was surgical aortic valve replacement (SAVR, AVR). Although hi ...
Depression, Heart Rate Variability, And Acute Myocardial Infarction
... Recovery in Coronary Heart Disease (ENRICHD) clinical trial. Details of the methods of the ENRICHD study have been reported previously.20 Briefly, patients with a recent (ⱕ28 days) acute MI who were depressed or socially isolated were randomly assigned to usual care or a cognitive-behavioral interve ...
... Recovery in Coronary Heart Disease (ENRICHD) clinical trial. Details of the methods of the ENRICHD study have been reported previously.20 Briefly, patients with a recent (ⱕ28 days) acute MI who were depressed or socially isolated were randomly assigned to usual care or a cognitive-behavioral interve ...
BNP JH - Public Health Wales
... and referrals of patients to specialists. The ELISA test, which allows bedside testing and provides results in a few minutes, performed somewhat better than the RIA tests, which must be sent to a laboratory, but it is more costly than RIA. The effect of introduction of such tests on patient outcomes ...
... and referrals of patients to specialists. The ELISA test, which allows bedside testing and provides results in a few minutes, performed somewhat better than the RIA tests, which must be sent to a laboratory, but it is more costly than RIA. The effect of introduction of such tests on patient outcomes ...
Adult Cardiology Advanced Training Curriculum
... demonstrate an understanding of and commitment to the role of research in advancing medical care of cardiovascular disease ...
... demonstrate an understanding of and commitment to the role of research in advancing medical care of cardiovascular disease ...
Increased serum cystatin C is a predictive factor for renal outcome in
... improve mortality and renal outcome, (23-25) while other studies failed to find any improvement. (26-28) Consequently, there are no indicators for the prophylactic RRT strategy for these acute renal failure or AKI patients. The present serum cystatin C data delineated the RD high-risk group, which ma ...
... improve mortality and renal outcome, (23-25) while other studies failed to find any improvement. (26-28) Consequently, there are no indicators for the prophylactic RRT strategy for these acute renal failure or AKI patients. The present serum cystatin C data delineated the RD high-risk group, which ma ...
pericardial effusion
... with a consequent increase in intrapericardial pressure. This results in diastolic compression of the heart, predominantly the thinner, more compliant right ventricle, because the pressure within the ventricular chamber is lower than the pressure within the pericardial space. A compressed right vent ...
... with a consequent increase in intrapericardial pressure. This results in diastolic compression of the heart, predominantly the thinner, more compliant right ventricle, because the pressure within the ventricular chamber is lower than the pressure within the pericardial space. A compressed right vent ...
... 32). After the primary results of the BART trial were gradually revealed, the US Food and Drug Administration (FDA) announced on November 5, 2007, that Trasylol (aprotinin) manufacturer (i.e. Bayer) should halt the marketing of the drug until more comprehensive studies would lead into a decision. Th ...
for patients chronic heart failure
... measure your pulse rate; measure your blood pressure; take some blood and urine to find out if you have anaemia, liver damage, kidney damage or thyroid disease; and take an x-ray of your chest. ...
... measure your pulse rate; measure your blood pressure; take some blood and urine to find out if you have anaemia, liver damage, kidney damage or thyroid disease; and take an x-ray of your chest. ...
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
... ABSTRACT: The efficacy and safety of combining bosentan, an orally active dual endothelin receptor antagonist and epoprostenol, a continuously infused prostaglandin, in the treatment of pulmonary arterial hypertension (PAH) was investigated. In this double-blind, placebo-controlled prospective study ...
... ABSTRACT: The efficacy and safety of combining bosentan, an orally active dual endothelin receptor antagonist and epoprostenol, a continuously infused prostaglandin, in the treatment of pulmonary arterial hypertension (PAH) was investigated. In this double-blind, placebo-controlled prospective study ...
Left Ventricular Diastolic Function Is Closely Associated With
... (3) LA anterior-posterior diameter >55 mm measured by transthoracic echocardiography (TTE); (4) the presence of intracardiac thrombi; (5) AF with significant valvular disease or structural heart disease; (6) previous AF ablation; and (7) history of cardiac surgery. All subjects underwent TEE, TTE, a ...
... (3) LA anterior-posterior diameter >55 mm measured by transthoracic echocardiography (TTE); (4) the presence of intracardiac thrombi; (5) AF with significant valvular disease or structural heart disease; (6) previous AF ablation; and (7) history of cardiac surgery. All subjects underwent TEE, TTE, a ...
ACLS Pharmacology/Algorithms Algorithms Primary ABCD Survey
... IV infusion of 30ml/kg of NS cooled to 4C over 30 minutes Cooling blankets not available here, didn’t work as well. ...
... IV infusion of 30ml/kg of NS cooled to 4C over 30 minutes Cooling blankets not available here, didn’t work as well. ...
Double heart rupture after acute myocardial infarction: A
... presence of blood clot, although it is not enough for a complete diagnosis without direct view of the rupture. This emphasizes the need for better education and best echo machines in intensive care units for better and faster diagnosis of acute myocardial infarction complications. VSR as a mechanica ...
... presence of blood clot, although it is not enough for a complete diagnosis without direct view of the rupture. This emphasizes the need for better education and best echo machines in intensive care units for better and faster diagnosis of acute myocardial infarction complications. VSR as a mechanica ...
- American Heart Journal
... Use of other medications of proven benefit increased with the number of atherothrombotic beds affected among all CrCl subgroups: β-blockers (eg, among patients with severe CKD, β-blockers were prescribed among 34.9%, 48.5%, 56.7%, 51.0%, of patients with no, 1, 2, or 3 atherothrombotic locations, re ...
... Use of other medications of proven benefit increased with the number of atherothrombotic beds affected among all CrCl subgroups: β-blockers (eg, among patients with severe CKD, β-blockers were prescribed among 34.9%, 48.5%, 56.7%, 51.0%, of patients with no, 1, 2, or 3 atherothrombotic locations, re ...
Drugs That May Cause or Exacerbate Heart Failure
... In the general population, patients with ≥5 chronic conditions have an average of 14 physician visits per year compared with only 1.5 for those with no chronic conditions.8–11 Medicare beneficiaries with HF see 15 to 23 different providers annually in both the inpatient and outpatient settings, whic ...
... In the general population, patients with ≥5 chronic conditions have an average of 14 physician visits per year compared with only 1.5 for those with no chronic conditions.8–11 Medicare beneficiaries with HF see 15 to 23 different providers annually in both the inpatient and outpatient settings, whic ...
diseases of the cardiovascular system
... – ____________________________ – Systolic murmur (soft – moderate) at the left heart base – ECG: evidence of left ventricular enlargement - ↑ ...
... – ____________________________ – Systolic murmur (soft – moderate) at the left heart base – ECG: evidence of left ventricular enlargement - ↑ ...
Double-Outlet Left Ventricle with Ebstein Anomaly in a Neonate with
... right ventricle.1-3 It is difficult to use embryologic basis to describe the existence of DOLV. Manner et al.4 tried to explain it by an excessive leftward shift of the embryonic conotruncus, anomalous differential conal growth, or absorption or malorientation of the subarterial portion of the ventr ...
... right ventricle.1-3 It is difficult to use embryologic basis to describe the existence of DOLV. Manner et al.4 tried to explain it by an excessive leftward shift of the embryonic conotruncus, anomalous differential conal growth, or absorption or malorientation of the subarterial portion of the ventr ...
tmt 1
... no association with ischemia. Even up to 1 cm of ST depression can occur in healthy normal subjects. There is no level of ST-segment depression that confers diagnostic significance in left bundle-branch block. ...
... no association with ischemia. Even up to 1 cm of ST depression can occur in healthy normal subjects. There is no level of ST-segment depression that confers diagnostic significance in left bundle-branch block. ...
10 Chapter General Discussion
... the plasma membrane, via a complex interplay between binding of NO to both heme and nonheme sites of sGC47,62,63. Stimulated sGC subsequently enhances cGMP generation, which activates its primary effector kinase PKG27,47. In turn, PKG phosphorylates a vast number of target proteins, exerting a wide ...
... the plasma membrane, via a complex interplay between binding of NO to both heme and nonheme sites of sGC47,62,63. Stimulated sGC subsequently enhances cGMP generation, which activates its primary effector kinase PKG27,47. In turn, PKG phosphorylates a vast number of target proteins, exerting a wide ...
ECG Challenge: Chest Pain and Palpitations in a Young Woman
... A 35-year-old woman presents to the emergency department with palpitations and chest pain. She is aware of her heart beating fast but not irregularly. She notes associated discomfort in the center of her chest. She denies dyspnea, light-headedness, diaphoresis, and nausea. Her medical history is rem ...
... A 35-year-old woman presents to the emergency department with palpitations and chest pain. She is aware of her heart beating fast but not irregularly. She notes associated discomfort in the center of her chest. She denies dyspnea, light-headedness, diaphoresis, and nausea. Her medical history is rem ...
N-terminal pro B-type natriuretic peptide (NT
... excluding acute heart failure are: NT-proBNP less than 300 ng/L or BNP less than 100 ng/L. If these levels are exceeded, echocardiography is recommended within 48 hours to guide early specialist management. The NICE clinical guideline CG108 (2010) on the management of chronic heart failure in adult ...
... excluding acute heart failure are: NT-proBNP less than 300 ng/L or BNP less than 100 ng/L. If these levels are exceeded, echocardiography is recommended within 48 hours to guide early specialist management. The NICE clinical guideline CG108 (2010) on the management of chronic heart failure in adult ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.